Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review
DOI: https://doi.org/10.2147/PHMT.S366636
2023-05-31
Pediatric Health, Medicine and Therapeutics
Abstract:Anna Maria Testi, Maria Luisa Moleti, Alessia Angi, Simona Bianchi, Walter Barberi, Saveria Capria Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy Correspondence: Anna Maria Testi, Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Via Benevento 6, Rome, 00161, Italy, Tel +39-06-49974731, Fax +39-06-44241984, Email Autologous stem cell transplantation (auto-HSCT) is a part of the therapeutic strategy for various oncohematological diseases. The auto-HSCT procedure enables hematological recovery after high-dose chemotherapy, otherwise not tolerable, by the infusion of autologous hematopoietic stem cells. Unlike allogeneic transplant (allo-HSCT), auto-HSCT has the advantage of lacking acute-graft-versus-host disease (GVHD) and prolonged immunosuppression, however, these advantages are counterbalanced by the absence of graft-versus-leukemia. Moreover, in hematological malignancies, the autologous hematopoietic stem cell source may be contaminated by neoplastic cells, leading to disease reappearance. In recent years, allogeneic transplant-related mortality (TRM) has progressively decreased, almost approaching auto-TRM, and many alternative donor sources are available for the majority of patients eligible for transplant procedures. In adults, the role of auto-HSCT compared to conventional chemotherapy (CT) in hematological malignancies has been well defined in many extended randomized trials; however, such trials are lacking in pediatric cohorts. Therefore, the role of auto-HSCT in pediatric oncohematology is limited, in both first- and second-line therapies and still remains to be defined. Nowadays, the accurate stratification in risk groups, according to the biological characteristics of the tumors and therapy response, and the introduction of new biological therapies, have to be taken into account in order to assign auto-HSCT a precise role in the therapeutic strategies, also considering that in the developmental age, auto-HSCT has a clear advantage over allo-HSCT, in terms of late sequelae, such as organ damage and second neoplasms. The purpose of this review is to report the results obtained with auto-HSCT in the different pediatric oncohematological diseases, focusing on the most significant literature data in the context of the various diseases and discussing this data in the light of the current therapeutic landscape. Keywords: autologous stem cell transplant, pediatric age, acute leukemia, chronic myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma The current probability of event-free survival (EFS) and overall survival (OS), for children with acute myeloid leukemia (AML) ranges between 45–50% and 65–70%, at 3–10 years, respectively. 1 Improvement of prognosis in children, but also adults, is due to better patient stratification in risk groups, which has made it possible to adapt the treatment to the clinical-biological characteristics of the disease. Allo-HSCT has increasingly been used in high-risk (HR) patients, and the improvement of supportive therapy and the optimization of induction and consolidation strategies have decreased therapy-related toxicity. Currently, new target therapies are also beginning to be used in pediatric age. 2 Over the past years, randomized studies have been carried out to clarify the role of auto-HSCT in AML patients in first remission (CR1) (Table 1). 2 Two previous meta-analyses showed that auto-HSCT, compared with standard consolidation CT, improved the EFS but not the OS. 3–5 In children with AML in CR1, auto-HSCT seemed to decrease the number of relapses and, consequently, improve disease-free survival (DFS) and OS. 6 Data from 13 studies of 12 randomized controlled trials (12 adult, 9 pediatric), including a total of 3027 patients (377 children), were collected. 3,4 The conditioning regimen usually included Busulfan (BU) and Cyclophosphamide (CY), however, in one trial bone marrow cells were in vitro chemo-purged with 4-hydroperoxycyclophosphamide (4-HC). Auto-HSCT, in adult AML patients in CR1, improved DFS compared with CT (HR = 0.98; 95% CI = 0.80–0.98); in children, there were no statistical differences in relapse incidence, TRM, DFS and OS (Table 1). 7–11 The authors concluded that in children and adolescents with CR1 AML, auto-HSCT does not add benefit compared to CT. Furthermore, the late toxicity associated with the pre-auto-HSCT conditioning regimen has to be considered in young patients who have a longer life expectancy. 12 Table 1 Results of Autologous Hematopoietic Stem Cell Transplant in Pediatric Acute Myeloid Leukemia in First Complete Remission Subsequently, Pession et al published data on 482 children with de novo AML treated with the Associazione Italian -Abstract Truncated-